Cargando…

Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation

Adult acute lymphoblastic leukemia (ALL) with BCR-ABL1 rearrangement (Philadelphia chromosome, Ph) is a hematological aggressive disease with a fatal outcome in more than 50% of cases. Tyrosine kinase inhibitors (TKIs) targeting the activity of BCR-ABL1 protein have improved the prognosis; however,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giudice, Valentina, Ghelli Luserna di Rorà, Andrea, Serio, Bianca, Guariglia, Roberto, Giannini, Maria Benedetta, Ferrari, Anna, Simonetti, Giorgia, Selleri, Carmine, Martinelli, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765866/ https://www.ncbi.nlm.nih.gov/pubmed/33419251 http://dx.doi.org/10.3390/ijms21249724

Ejemplares similares

The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?
por: Ghelli Luserna di Rorà, Andrea, et al.
Publicado: (2019)

A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
por: Ghelli Luserna di Rorà, Andrea, et al.
Publicado: (2020)

Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon
por: Ghelli Luserna di Rorà, Andrea, et al.
Publicado: (2023)

Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia
por: Wang, Huafeng, et al.
Publicado: (2022)

CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies
por: Bruno, Samantha, et al.
Publicado: (2022)

Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies
por: Padella, Antonella, et al.
Publicado: (2022)

Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations
por: Ferrari, Anna, et al.
Publicado: (2023)

Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation
por: Okabe, Seiichi, et al.
Publicado: (2015)

The cell cycle checkpoint inhibitors in the treatment of leukemias
por: Ghelli Luserna di Rora’, A., et al.
Publicado: (2017)

Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
por: Gottardi, Michele, et al.
Publicado: (2021)

Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia
por: Ghelli Luserna Di Rorà, Andrea, et al.
Publicado: (2019)

Synthesis of Novel Tryptamine Derivatives and Their Biological Activity as Antitumor Agents
por: Simonetti, Giorgia, et al.
Publicado: (2021)

Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia
por: Rorà, Andrea Ghelli Luserna Di, et al.
Publicado: (2016)

Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells
por: Ghelli Luserna Di Rorà, Andrea, et al.
Publicado: (2021)

Giant plasma cells with multiple immature nuclei in a young woman with newly diagnosed multiple myeloma
por: Giudice, Valentina, et al.
Publicado: (2022)

INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph(+) acute lymphoblastic leukemia
por: Martinelli, Giovanni, et al.
Publicado: (2022)

Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients
por: Trino, Stefania, et al.
Publicado: (2016)

Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a
por: Fontana, Maria Chiara, et al.
Publicado: (2021)

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation
por: Nicolini, Franck E., et al.
Publicado: (2017)

Efficacy of Decitabine and Venetoclax as Salvage and Bridge Therapy to Haploidentical Hematopoietic Stem Cell Transplantation in a Multiresistant Acute Myeloid Leukemia Patient
por: Serio, Bianca, et al.
Publicado: (2022)

T315I clone selection in a Ph+ all patient under low‐dose ponatinib maintenance
por: Noetzli, Jasmine, et al.
Publicado: (2017)

Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway
por: Padella, Antonella, et al.
Publicado: (2021)

Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial
por: Cerchione, Claudio, et al.
Publicado: (2020)

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
por: Oaxaca, Derrick M., et al.
Publicado: (2016)

Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions
por: Beeharry, Neil, et al.
Publicado: (2015)

A Rare Immune-Related Mesenteric and retroperitoneal serositis in a Multi-Refractory Hodgkin Lymphoma Patient Successfully Treated with Chylolymphostatic Surgery
por: D’Addona, Matteo, et al.
Publicado: (2023)

PB1763: A PHASE 1/2 STUDY TO EVALUATE PONATINIB WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RELAPSED/RESISTANT/INTOLERANT PHILADELPHIA CHROMOSOME–POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR WITH T315I MUTATION
por: Gore, L., et al.
Publicado: (2022)

Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia
por: Price, Kimberly E, et al.
Publicado: (2013)

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
por: Arbour, Kathryn C., et al.
Publicado: (2021)

Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
por: De Novellis, Danilo, et al.
Publicado: (2022)

Monitoring Ponatinib in a Child with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Tanimura, Kazuki, et al.
Publicado: (2021)

Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia
por: Ribera, Josep-Maria, et al.
Publicado: (2022)

Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia
por: Ghelli Luserna Di Rorà, Andrea, et al.
Publicado: (2018)

In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia
por: Iacobucci, Ilaria, et al.
Publicado: (2015)

Efficacy and safety of splenectomy in adult autoimmune hemolytic anemia
por: Giudice, Valentina, et al.
Publicado: (2016)

Secretory and Membrane-Associated Biomarkers of Mast Cell Activation and Proliferation
por: Parente, Roberta, et al.
Publicado: (2023)

Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma
por: Derenzini, Enrico, et al.
Publicado: (2015)

Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma
por: Derenzini, Enrico, et al.
Publicado: (2015)

CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma
por: Martino, Massimo, et al.
Publicado: (2021)

P1544: IMPACT OF SARS-COV 2 INFECTION, IN TREATED NHL-B AND HD, AFTER VACCINATION AND PREVENTIVE THERAPY WITH ANTIBODIES: OUR EXPERIENCE
por: Pezzullo, Luca, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_45bdm6s95ddhk9ksoj258aqunv